Therapeutic Response

5q deletion status confers therapeutic sensitivity to Lenalidomide in patients with Myelodysplastic Syndromes.

Statements

Source and description
Revlimid (lenalidomide) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to lenalidomide for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.
Revlimid (lenalidomide) [product monograph]. HC. Health Canada approved lenalidomide for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogentic abnormalities.